Diamond Biotech Investment has divested its entire stake in Unified Biotech for approximately NT$3.336 billion, engaging both Zhongtian Biotech and international institutional investors to enhance growth in the biotech sector.

Target Company Overview

This transaction involves Diamond Biotech Investment, under the Zhongtian Biotech Group, disposing of its entire stake in Unified Biotech, totaling 26,691,358 shares. The share price for the transaction is set above NT$125, with the total consideration amounting to NT$3.336 billion. Diamond's decision to sell is aligned with its commitment made during its IPO application process, which was approved by its Audit Committee and Board of Directors.

The sale is expected to involve multiple parties, including Zhongtian Biotech and two long-term institutional investors from Europe and Asia. The share price represents a discount of no more than 9.4% compared to Unified Biotech’s recent closing price of NT$138.

Industry Overview in Taiwan

The biotech and pharmaceuticals industry in Taiwan has been rapidly growing, driven by advancements in research and development. Many companies are increasingly focusing on innovative drug development, particularly in emerg